GlassScriptPhysician profile
Kian Adabi
NPI 1528626710
$8,980.52
in general payments reported to CMS, 2019-2025
16 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,640 · 2024: $4,962 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,581 · Travel and Lodging: $3,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,581.18 |
| Travel and Lodging | $3,399.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,322.78 | 2023-2025 | Percept PC Brainsense, Activa PC |
| Abbott Laboratories | $1,357.83 | 2024 | Infinity |
| Boston Scientific Corporation | $1,328.16 | 2024-2025 | Vercise, General - Dbs |
| Abbvie INC. | $957.55 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $792.67 | 2023-2024 | Nuplazid, Daybue |
| Amneal Pharmaceuticals LLC | $475.78 | 2023-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Merz Pharmaceuticals, LLC | $443.39 | 2023-2025 | Xeomin |
| Kyowa Kirin, INC. | $380.96 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $202.85 | 2023-2024 | Nuedexta |
| Neurocrine Biosciences, INC. | $148.05 | 2024 | Ingrezza |
| Revance Therapeutics, INC. | $131.45 | 2025 | Daxxify |
| Mdd US Operations, LLC | $123.74 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $123.22 | 2024-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $118.60 | 2023 | Epidiolex |
| Azurity Pharmaceuticals, INC. | $52.85 | 2024 | Horizant |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.64 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kian Adabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.